title: Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group.
abstract: 118 patients with complicated intra-abdominal infections participated in an open randomized comparative multicenter trial in order to compare the clinical and microbiological efficacy and safety of biapenem with imipenem/cilastatin (Tienam). 31 men and 27 women (mean age 52.3 years) were enrolled in the biapenem group, and 43 men and 17 women (mean age 52.3 years) in the imipenem/cilastatin group. The patients received either biapenem 500 mg every 8 h or imipenem/cilastatin 500 mg/500 mg every 6 h by intravenous infusion for up to 13 days (mean 6.5 days). 28/43 evaluable patients (65.1%) receiving biapenem and 27/40 evaluable patients (67.5%) in the imipenem/cilastatin group were clinically cured. The microbiological response was satisfactory in 28/43 evaluable patients (65.1%) receiving biapenem and in 27/40 evaluable patients (67.5%) receiving imipenem/cilastatin. No significant differences in clinical or microbiological efficacy between the two treatment groups were found. The present study shows that biapenem may be useful in the treatment of intra-abdominal infections.
authors.affiliation: Stockholm Söder Hospital, Sweden.
authors.forename: B
authors.initials: B
authors.lastname: Brismar
authors.forename: J E
authors.initials: JE
authors.lastname: Akerlund
authors.forename: S
authors.initials: S
authors.lastname: Sjöstedt
authors.forename: C
authors.initials: C
authors.lastname: Johansson
authors.forename: A
authors.initials: A
authors.lastname: Törnqvist
authors.forename: B
authors.initials: B
authors.lastname: Bäckstrand
authors.forename: H
authors.initials: H
authors.lastname: Bång
authors.forename: L
authors.initials: L
authors.lastname: Andåker
authors.forename: P O
authors.initials: PO
authors.lastname: Gustafsson
authors.forename: N
authors.initials: N
authors.lastname: Darle
authors.forename: M
authors.initials: M
authors.lastname: Angerås
authors.forename: A
authors.initials: A
authors.lastname: Falk
authors.forename: G
authors.initials: G
authors.lastname: Tunevall
authors.forename: B
authors.initials: B
authors.lastname: Kasholm-Tengve
authors.forename: T
authors.initials: T
authors.lastname: Skau
authors.forename: P O
authors.initials: PO
authors.lastname: Nyström
authors.forename: T
authors.initials: T
authors.lastname: Gasslander
authors.forename: A
authors.initials: A
authors.lastname: Hagelbäck
authors.forename: B
authors.initials: B
authors.lastname: Olsson-Liljequist
authors.forename: A E
authors.initials: AE
authors.lastname: Eklund
authors.forename: C E
authors.initials: CE
authors.lastname: Nord
mesh_terms: D018806:APACHE; D000005:Abdomen / Q000382:microbiology*; D018784:Abdominal Abscess / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000188:drug therapy*; D015377:Cilastatin / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015378:Imipenem / Q000009:adverse effects / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012449:Safety; D013548:Sweden; D013845:Thienamycins / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D011480:Protease Inhibitors; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem; C065257:biapenem